0001415889-22-006711.txt : 20220617 0001415889-22-006711.hdr.sgml : 20220617 20220617161047 ACCESSION NUMBER: 0001415889-22-006711 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220615 FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 221023905 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-06172022_010630.xml X0306 4 2022-06-15 0000855654 ImmunoGen, Inc. IMGN 0001557290 Arbuckle Stuart A C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 true false false false Deferred Share Unit 0 2022-06-15 4 A 0 15000 0 A Common Stock 15000 63000 D Stock Option (right to buy) 3.37 2022-06-15 4 A 0 44000 3.37 A 2032-06-15 Common Stock 44000 44000 D The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date. /s/ Renee Lentini, Attorney-in-Fact 2022-06-17